Structure Therapeutics (GPCR)

Executive Summary

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company leveraging its proprietary structure-based drug discovery platform to develop oral small molecule therapies targeting G protein-coupled receptors (GPCRs) for metabolic and pulmonary diseases. Its lead asset, aleniglipron, is an oral GLP-1 receptor agonist being investigated for obesity and overweight. The company is advancing multiple Phase 2 trials evaluating aleniglipron for chronic weight management, with data readouts anticipated in the second half of 2026. These trials include dose-ranging studies and comparisons with placebo, aiming to demonstrate efficacy and safety. Additionally, the company has completed early-phase studies for GSBR-1290, another oral GLP-1 agonist, which showed promising weight loss results. Structure Therapeutics is well-positioned in the competitive metabolic disease space, with its platform enabling the design of oral alternatives to injectable therapies like semaglutide. The company's success depends on generating compelling Phase 2 data that supports advancement to pivotal trials and potential regulatory filing. With a strong cash position and a focused strategy, Structure Therapeutics represents a high-upside opportunity in the obesity treatment market, though risks include intense competition and clinical trial execution.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 aleniglipron obesity data (dose-ranging study)60% success
• Q4 2026Phase 2 aleniglipron obesity/diabetes data (combination with metformin)55% success